Gedeon Richter licenses KV products; Canadian court rejects copycat Viagra;

> Hungary's Gedeon Richter signed a deal with U.S.-based KV Pharmaceutical for licensing rights to some of KV's technologies and products. Report

> The Federal Court of Canada rejected Novapharm's bid to market a generic version of Pfizer's erectile dysfunction drug Viagra. Report

> The recall of nasal versions of Matrixx Initiatives' Zicam cold remedies could cost as much as $10 million, the company's top executive said. Report

> The FDA approved Allergan's Ozurdex treatment for the retinal disease macular edema. Report

> Pharma pumped $28.7 billion into New Jersey's sputtering economy last year even as the largest companies steadily slashed jobs, according to a statewide trade group. Report

> Bristol-Myers Squibb and AstraZeneca joined forces with Diabetes UK to launch a national patient survey on the effects of hypoglycaemia. Report

> The Medicines Company said FDA granted pediatric exclusivity for Angiomax, its anticoagulant, staving off generic competition till September 2010. Report

> Abbott Laboratories and Dey asked a Massachusetts federal court to sanction the U.S. Department of Justice for destroying evidence in a multidistrict wholesale drug pricing case. Report

Biotech News

> Massachusetts-based ImmunoGen is offering 5 million shares of its stock at a price of $7.00 per share. The company is hoping to raise a total of $33 million after underwriting discounts, commissions and expenses. Report

> Aastrom's shares are up on the news that the FDA has lifted a clinical hold on the company's Phase II congestive heart failure trial. Report

> Opko Health has decided to move into vaccine development and diagnostics following a crucial clinical trial failure in opthalmology last March. Report

> The FDA has approved Novartis' Ilaris (also known as canakinumab or ACZ885), a treatment for children and adults with cryopyrin-associated periodic syndrome (CAPS). Report

And Finally... Smart idea? Healthy people should be able to take the anti-hyperactivity drug Ritalin to boost brain power, a UK ethicist says. Report

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.